RT Journal Article
SR Electronic
T1 Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e005847
DO 10.1136/jitc-2022-005847
VO 11
IS 1
A1 Julia Karbach
A1 Dragan Kiselicki
A1 Kathrin Brand
A1 Claudia Wahle
A1 Evgueni Sinelnikov
A1 Dirk Gustavus
A1 Hans Hoffmeister
A1 Hans-Bernd Prisack
A1 Akin Atmaca
A1 Elke Jäger
YR 2023
UL http://jitc.bmj.com/content/11/1/e005847.abstract
AB Adoptive transfer of autologous tumor-specific lymphocytes represents a viable treatment method for patients with advanced malignancies. Here, we report a patient’s case with metastatic hormone-refractory New York esophageal squamous cell carcinoma 1 (NY-ESO-1) expressing prostate cancer treated with in vitro expanded tumor-infiltrating lymphocytes (TILs) in conjunction with IL-2 and immune-checkpoint blockade. Complete and durable tumor remission was observed after three TIL infusions consisting of 1.4×109, 2.0×109, and 8.0×109 T cells, respectively, lasting now for more than 3.5 years. Immunological correlates to the clinical development were the decrease of tumor-driven NY-ESO-1 serum antibody and the drop of prostate-specific antigen to <0.01 µg/L. TILs were reactive against cancer-testis antigen NY-ESO-1, individual tumor mutational proteins (eg, PRPF8, TRPS1), and the androgen receptor splice variant 12.